Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent

Objective: Many biologic agents cause some degree of immunosuppression, which can increase the risk of reactivation of tuberculosis infection (TBI). This risk is variable between individual biologics. We aimed to assess current (and recommended) clinical practice of TBI screening and treatment among...

Full description

Saved in:

Bibliographic Details
Published in:	Jornal brasileiro de pneumologia Vol. 50; no. 4; p. e20240082
Main Authors:	Sultana1,2, Adiba, Battista Migliori3, Giovanni, D’Ambrosio,4, Lia, García-García5, José-María, Rossato Silva6, Denise, Adrian Rendon5, Luis, R Codecasa7, Luigi, Blanc8, Francois-Xavier, Tiberi9, Simon, W M Ong10,11,12, Catherine, Heffernan13, Courtney, Sotgiu14, Giovanni, Centis3, Rosella, Caroline Dobler1,2, Claudia, Network, The Global Tuberculosis
Format:	Journal Article
Language:	English
Published:	Brazil Sociedade Brasileira de Pneumologia e Tisiologia 2024
Subjects:	Biological products Biological Products - adverse effects Biological Products - therapeutic use Humans Immunosuppression therapy Latent tuberculosis Latent Tuberculosis - diagnosis Latent Tuberculosis - drug therapy Life Sciences Mass screening Mass Screening - methods Original Recurrence RESPIRATORY SYSTEM Risk Factors Surveys and Questionnaires Tuberculosis Latent tuberculosis Recurrence Latent tuberculosis Biological products Immunosuppression therapy Recurrence Mass screening Biological products Immunosuppression therapy Mass screening
ISSN:	1806-3756, 1806-3713, 1806-3756
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!